Spots Global Cancer Trial Database for recurrent endometrial cancer
Every month we try and update this database with for recurrent endometrial cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | NCT03694262 | Endometrial Can... Uterine Carcino... | Rucaparib Bevacizumab Atezolizumab | 18 Years - | Medical College of Wisconsin | |
| Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients | NCT02755844 | Recurrent Endom... | Olaparib metformin metronomic cycl... | 18 Years - 81 Years | Hospices Civils de Lyon | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors | NCT05798611 | Advanced Solid ... Recurrent Endom... Metastatic Canc... | ART0380 | 18 Years - | Artios Pharma Ltd | |
| Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | NCT02549989 | Endometrial Can... Recurrent Endom... | LY3023414 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | NCT05263492 | Endometrial Can... Mismatch Repair... Recurrent Endom... | Lenvatinib Pembrolizumab | 18 Years - | Virginia Commonwealth University | |
| RAD001 in Recurrent Endometrial Cancer Patients | NCT00087685 | Endometrial Can... | RAD001 | - | M.D. Anderson Cancer Center | |
| A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | NCT01454479 | Recurrent Endom... | Lapatinib and i... | 20 Years - 75 Years | Chang Gung Memorial Hospital | |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | NCT03277482 | Recurrent Gynec... Metastatic Cerv... Metastatic Ovar... Metastatic Vagi... Metastatic Vulv... Metastatic Endo... Recurrent Cervi... Recurrent Ovari... Recurrent Vagin... Recurrent Vulva... Recurrent Endom... | Durvalumab Tremelimumab Radiation Thera... | 18 Years - | Dana-Farber Cancer Institute | |
| Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | NCT02549989 | Endometrial Can... Recurrent Endom... | LY3023414 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of ART0380 in Patients With Biologically Selected Solid Tumors | NCT05798611 | Advanced Solid ... Recurrent Endom... Metastatic Canc... | ART0380 | 18 Years - | Artios Pharma Ltd | |
| A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | NCT01454479 | Recurrent Endom... | Lapatinib and i... | 20 Years - 75 Years | Chang Gung Memorial Hospital | |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | NCT03694262 | Endometrial Can... Uterine Carcino... | Rucaparib Bevacizumab Atezolizumab | 18 Years - | Medical College of Wisconsin | |
| Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | NCT00545792 | Cervical Cancer Endometrial Can... Ovarian Cancer Vaginal Cancer Carcinoma of th... | Avastin | 18 Years - | Dana-Farber Cancer Institute | |
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | NCT04906382 | Lynch Syndrome Recurrent Endom... Recurrent Endom... Recurrent Uteri... Mismatch Repair... Recurrent Endom... Metastatic Endo... | Biopsy Carboplatin Paclitaxel Tislelizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients | NCT02755844 | Recurrent Endom... | Olaparib metformin metronomic cycl... | 18 Years - 81 Years | Hospices Civils de Lyon | |
| RAD001 in Recurrent Endometrial Cancer Patients | NCT00087685 | Endometrial Can... | RAD001 | - | M.D. Anderson Cancer Center | |
| Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | NCT02899793 | Recurrent Endom... | Pembrolizumab | 18 Years - 100 Years | Yale University | |
| ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | NCT06366347 | Endometrial Can... Recurrent Endom... TP53 | Abemaciclib Letrozole Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | NCT05419817 | Recurrent Endom... Solid Tumors | pembrolizumab Sitravatinib | 18 Years - | University of Pittsburgh | |
| Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | NCT05263492 | Endometrial Can... Mismatch Repair... Recurrent Endom... | Lenvatinib Pembrolizumab | 18 Years - | Virginia Commonwealth University | |
| Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | NCT03564340 | Recurrent Ovari... Recurrent Fallo... Recurrent Prima... Recurrent Endom... | REGN4018 cemiplimab Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | NCT00545792 | Cervical Cancer Endometrial Can... Ovarian Cancer Vaginal Cancer Carcinoma of th... | Avastin | 18 Years - | Dana-Farber Cancer Institute | |
| Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | NCT02899793 | Recurrent Endom... | Pembrolizumab | 18 Years - 100 Years | Yale University | |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | NCT02788708 | Fallopian Tube ... Recurrent Ovari... Primary Periton... Recurrent Endom... | Lenvatinib Mesy... Paclitaxel Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
